Sysmex Gets Japanese Manufacturing, Marketing Approval for Colorectal Cancer Screening Assay
The firm believes that physicians can use information from the cell-free DNA analyzed by the assay to determine whether to use anti-EGFR drugs during treatment.
The results confirmed that circulating mutations can be reliably detected and changed during treatment, and showed that they could be a valuable prognostic biomarker.
Novartis PI3K Inhibitor Effective in Breast Cancer Subset; Psych Toxicities Dampen Enthusiasm
Amid concerns about buparlisib's toxicity profile, a study suggests there might be a benefit for a subpopulation of patients with a more targeted PI3K inhibitor.
The firms will set up sites for OncoBEAM RAS CRC in Argentina, Brazil, Malaysia, Indonesia, Vietnam, and India, and present data at major medical conferences.
Merck KGaA, Sysmex Inostics Garner CE Mark for Liquid Biopsy CRC Test
The firms now plan to market the test in Europe, Asia, and Australia as a tool oncologists can use to identify best responders to EGFR inhibitors.